Improving outcomes for patients with acute myeloid leukemia in first relapse: A single center experience

Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia

(2014) Naveen Pemmaraju et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation

(2013) F. Ravandi et al.   BLOOD

Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients withFLT3-ITD

(2013) Koichi Takahashi et al.   BRITISH JOURNAL OF HAEMATOLOGY

FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations

(2013) Sabine Kayser et al.   LEUKEMIA & LYMPHOMA

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Advances in Acute Myeloid Leukemia

(2011) Alan Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

(2010) F. Ravandi et al.   BLOOD

Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C

(2010) Pierre Fenaux et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse

(2010) S. Kurosawa et al.   HAEMATOLOGICA

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine

(2010) W. Blum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY